SYRE(Spyre Therapeutics, Inc.) · 财务报表

SYRE(Spyre Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$18.74M$2.33M$886.00K$0$0
毛利润—————
营业利润−$65.65M−$84.78M−$242.30M−$208.57M−$209.56M
净利润−$65.80M−$83.81M−$338.79M−$208.02M−$155.20M
经营现金流−$53.72M−$80.14M−$99.91M−$157.41M−$169.25M
自由现金流−$54.29M−$80.18M−$99.91M−$157.41M—
摊薄每股收益$-25.02$-24.86———

Spyre Therapeutics, Inc. SYRE